Adamis' specialty pharmaceuticals division, Adamis Labs, is currently developing products in the respiratory and allergy markets. This division's focus is to create low cost therapeutic alternatives to existing treatments. Adamis will pursue 505(b)(2) regulatory approval filings whenever possible in order to minimize costs and shorten the time to market.
New Agreement with 3M
Recently, Adamis fully acquired and exclusively licensed 3M Company's (NYSE:MMM) Taper Dry Powder Inhaler (DPI) technology under development for the treatment of asthma and chronic obstructive pulmonary disease (COPD). As a part of the agreement, Adamis will obtain worldwide rights to use this platform technology in all indications in the dry powder inhalation field. The unique design uses proprietary 3M technology to store active pharmaceutical ingredient (API) on a microstructured carrier tape. 3M will supply the drug delivery tape for the platform to Adamis under a separate supply agreement. ADMP's first product with this new technology will be the APC-5000 which will be designed to compete with other dry powder inhalers such as GlaxoSmithKline's (GSK) Advair Diskus® for the treatment of asthma and chronic obstructive pulmonary disease (COPD).